Table 1 Clinical and biological features of SLE and RA patients
SLE patients | n = 127 | RA patients | n = 100 |
|---|---|---|---|
Mean Age ± DS (years) | 32,48 ± 13,59 | Mean age ± DS (years) | 40,43 ± 14,48 |
Median of evolution ± DS (years) | 5 ± 4,96 | Median of evolution ± DS (months) | 120 ± 97,46 |
Sex ratio (Female/Male) | 6,47 (110/17) | Sex ratio (Female/Male) | 3,54 (78/22) |
Early onset before 40 years | 51 (51%) | ||
Cutaneous lesions n (%) | 77 (60,6%) | Bone erosions n (%) | 38 (38%) |
Arthritis n (%) | 97 (76,3%) | Subcutaneous nodules n (%) | 17 (17%) |
Nephritis n (%) | 68 (53,5%) | ||
Titer of ANA > 1/200 n (%) | 106 (83,4%) | Rheumatoid factor (RF) n (%) | 75 (75%) |
Anti-dsDNA antibodies (Abs) n (%) | 90 (70,8%) | Anti-CCP antibodies (ACCPA) n (%) | 73 (73%) |
Decreased complement activity (DCA) n (%) | 93 (73,2%) | HLA-DRB1*04 allele | 46 (46%) |
Shared epitope | 46 (46%) | ||
SLEDAI* ≥ 8 n (%) | 91 (71,6%) | Active RA (DAS28† ≥ 5,1) n (%) | 70 (70%) |
DAS28† (average ± DS) | 5,97 ± 1,72 |